Core Viewpoint - Sanofi has announced its acquisition of Vigil Neuroscience, enhancing its neurology pipeline with a focus on developing treatments for Alzheimer's disease, specifically through the investigational drug VG-3927 [1][5]. Company Overview - Sanofi is a global healthcare company dedicated to improving lives through innovative treatments and vaccines, emphasizing sustainability and social responsibility [10]. - Vigil Neuroscience is a clinical-stage biotechnology company focused on novel therapies for neurodegenerative diseases, particularly Alzheimer's [1][3]. Acquisition Details - Sanofi will acquire all outstanding common shares of Vigil for $8 per share, totaling an equity value of approximately $470 million on a fully diluted basis [8]. - Vigil's shareholders will also receive a contingent value right (CVR) entitling them to a deferred cash payment of $2 upon the first commercial sale of VG-3927 [8]. - The acquisition is expected to close in Q3 2025, pending customary conditions including shareholder approval and regulatory clearance [9]. Strategic Importance - The acquisition aligns with Sanofi's strategic focus on neurology and aims to leverage its expertise in immunology to address critical unmet needs in Alzheimer's treatment [2][5]. - VG-3927, an oral small molecule TREM2 agonist, is anticipated to enhance the neuroprotective function of microglia, potentially improving outcomes for Alzheimer's patients [1][3]. Market Context - Current Alzheimer's therapies do not halt or reverse disease progression, highlighting the urgent need for more effective treatment options [4]. - Sanofi's prior $40 million investment in Vigil demonstrates its proactive approach to securing innovative solutions in the healthcare sector [5].

Core Viewpoint - Sanofi has announced the acquisition of Vigil Neuroscience, Inc., enhancing its neurology pipeline with a focus on developing treatments for Alzheimer's disease, specifically through the investigational drug VG-3927 [1][5]. Group 1: Acquisition Details - Sanofi will acquire all outstanding common shares of Vigil for $8 per share, totaling an equity value of approximately $470 million on a fully diluted basis [8]. - Vigil's shareholders will also receive a contingent value right (CVR) entitling them to a deferred cash payment of $2 upon the first commercial sale of VG-3927 [8]. - The acquisition is expected to close in Q3 2025, subject to customary conditions including shareholder approval and regulatory clearances [9]. Group 2: Strategic Importance - This acquisition aligns with Sanofi's strategic focus on neurology and aims to address critical unmet needs in Alzheimer's treatment, where current therapies do not halt or reverse disease progression [4][2]. - The acquisition follows a $40 million strategic investment made by Sanofi in Vigil in June 2024, which included rights to negotiate for VG-3927 [5]. Group 3: Scientific Rationale - VG-3927 is an oral small molecule TREM2 agonist, which is expected to enhance the neuroprotective function of microglia in Alzheimer's disease [1]. - Activation of TREM2 is believed to improve microglial response to injury, potentially preventing neural degeneration associated with neurodegenerative diseases [3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-41200 VIGIL NEUROSCIENCE, INC. (Exact name of Registrant as specified in its Charter) De ...

Financial Performance - Cash, cash equivalents, and marketable securities were $87.1 million as of March 31, 2025, down from $97.8 million as of December 31, 2024[7] - Net loss for Q1 2025 was $22.4 million, compared to a net loss of $19.9 million in Q1 2024[7] - Total operating expenses for Q1 2025 were $23.5 million, compared to $21.4 million in Q1 2024[12] - General and Administrative (G&A) expenses for Q1 2025 were $7.0 million, consistent with $7.1 million reported in Q1 2024[7] - Research and Development (R&D) expenses for Q1 2025 were $16.5 million, an increase from $14.3 million in Q1 2024, driven by higher preclinical and manufacturing costs[7] - The company expects its cash runway to be sufficient to fund operations into 2026[9] Clinical Trials and Developments - The final analysis from the IGNITE Phase 2 clinical trial for iluzanebart is planned for Q2 2025, with an accelerated approval pathway being pursued[3] - VG-3927 showed a robust and dose-dependent reduction of sTREM2 of up to approximately 50% in the cerebral spinal fluid, demonstrating strong pharmacokinetics and pharmacodynamics[5] - The Phase 2 clinical trial for VG-3927 in Alzheimer's disease is expected to be initiated in Q3 2025[2] - The company plans to advance a once-daily oral dose of 25 mg of VG-3927 that fully engages the desired pharmacology[5]

Core Insights - Vigil Neuroscience is advancing its clinical programs, with key milestones expected in 2025, including the final analysis of iluzanebart in ALSP and the initiation of a Phase 2 trial for VG-3927 in Alzheimer's disease [1][2][3] Clinical Development Updates - The final analysis from the IGNITE Phase 2 clinical trial for iluzanebart is scheduled for Q2 2025, with plans for an accelerated approval pathway in ALSP [3] - VG-3927 has shown positive Phase 1 data, supporting the initiation of a Phase 2 trial in Q3 2025 for Alzheimer's disease [2][4] - The Phase 1 trial for VG-3927 included 115 participants, demonstrating a favorable safety profile and significant pharmacokinetic and pharmacodynamic results [4] Financial Performance - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities of $87.1 million, down from $97.8 million at the end of 2024, with expectations to fund operations into 2026 [9][13] - Research and Development (R&D) expenses for Q1 2025 were $16.5 million, an increase from $14.3 million in Q1 2024, driven by higher costs in preclinical and manufacturing activities [9][11] - The net loss for Q1 2025 was $22.4 million, compared to $19.9 million for the same period in 2024, with a net loss per share of $0.49 [9][11]